Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CRL 
Charles River Laboratories (CRL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CRL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -35.79% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.47B USD | Price to earnings Ratio 729.95 | 1Y Target Price 179.72 |
Price to earnings Ratio 729.95 | 1Y Target Price 179.72 | ||
Volume (30-day avg) 1347268 | Beta 1.45 | 52 Weeks Range 142.76 - 264.70 | Updated Date 04/1/2025 |
52 Weeks Range 142.76 - 264.70 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.55% | Operating Margin (TTM) 7.79% |
Management Effectiveness
Return on Assets (TTM) 4.34% | Return on Equity (TTM) 0.71% |
Valuation
Trailing PE 729.95 | Forward PE 15.46 | Enterprise Value 9995551205 | Price to Sales(TTM) 1.84 |
Enterprise Value 9995551205 | Price to Sales(TTM) 1.84 | ||
Enterprise Value to Revenue 2.47 | Enterprise Value to EBITDA 17.2 | Shares Outstanding 51141600 | Shares Floating 50574447 |
Shares Outstanding 51141600 | Shares Floating 50574447 | ||
Percent Insiders 0.94 | Percent Institutions 105.92 |
Analyst Ratings
Rating 3.24 | Target Price 215.27 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold 11 | Sell - | Strong Sell 3 | |
Strong Sell 3 |
Upturn AI SWOT
Charles River Laboratories
Company Overview
History and Background
Founded in 1947, Charles River Laboratories began as a small rodent breeding company. It has grown through acquisitions and organic expansion to become a leading provider of research models and preclinical and clinical laboratory services to the pharmaceutical, biotechnology, and government sectors.
Core Business Areas
- Research Models and Services (RMS): Provides laboratory animal models (primarily rodents) and related services, including genetic and health monitoring, to research institutions and pharmaceutical companies.
- Discovery and Safety Assessment (DSA): Offers preclinical discovery and safety assessment services, including in vitro and in vivo studies, toxicology, and pathology, to evaluate the safety and efficacy of drug candidates.
- Manufacturing Support (Manufacturing): Provides manufacturing support services, including testing of biologics and biosafety testing, to ensure the quality and safety of pharmaceutical products.
Leadership and Structure
James C. Foster is the Chairman, President, and CEO. The company has a hierarchical structure with various business units headed by senior executives.
Top Products and Market Share
Key Offerings
- Research Models: Laboratory animals, primarily rodents. Charles River is a dominant player in this market. Competitors include Envigo (now Inotiv), Taconic Biosciences, and Janvier Labs. Market share is estimated to be around 30-40% of the global research model market.
- Preclinical Services: Drug safety and efficacy testing. Charles River is a leading provider of these services. Competitors include Covance (Labcorp), WuXi AppTec, and Eurofins Scientific. Revenue from this segment is estimated to be a significant portion of the company's total revenue.
- Biologics Testing Solutions: Provides in vitro and in vivo testing of biologics, small molecules, and cell and gene therapies. Key competitor is WuXi AppTec and market share is a significant portion of total revenue.
Market Dynamics
Industry Overview
The industry is driven by increasing R&D spending in the pharmaceutical and biotechnology sectors, growing demand for drug safety testing, and advancements in drug discovery technologies. There is also growth in outsourcing of pre-clinical work.
Positioning
Charles River Laboratories is a leading player in the preclinical research and drug development market, with a strong reputation for quality and expertise. It benefits from long-standing relationships with pharmaceutical and biotechnology companies.
Total Addressable Market (TAM)
The total addressable market (TAM) for preclinical research and drug development is estimated to be in the tens of billions of dollars. Charles River is well-positioned to capture a significant portion of this market due to its broad range of services and global presence.
Upturn SWOT Analysis
Strengths
- Strong market position
- Diversified service offerings
- Global presence
- Established relationships with pharmaceutical and biotechnology companies
- Reputation for quality and expertise
Weaknesses
- High dependence on R&D spending in the pharmaceutical and biotechnology sectors
- Exposure to regulatory changes
- Integration risks associated with acquisitions
- Cost structure impacts margins.
- Competitive landscape with pricing pressure.
Opportunities
- Increasing outsourcing of preclinical research
- Growth in emerging markets
- Expanding service offerings through acquisitions
- Advancements in drug discovery technologies
- Growth in cell and gene therapy.
Threats
- Economic downturns affecting R&D spending
- Increased competition
- Regulatory changes impacting drug development
- Pricing pressure from customers
- Animal rights activism
Competitors and Market Share
Key Competitors
- LH
- WUXI
- INVT
Competitive Landscape
Charles River Laboratories has a strong market position due to its diversified service offerings and global presence. However, it faces competition from other large CROs and specialized providers.
Major Acquisitions
Vigene Biosciences
- Year: 2021
- Acquisition Price (USD millions): 292
- Strategic Rationale: Expanded gene therapy capabilities.
Growth Trajectory and Initiatives
Historical Growth: Charles River Laboratories has grown both organically and through acquisitions, expanding its service offerings and geographic reach.
Future Projections: Analyst estimates predict continued revenue growth for Charles River Laboratories, driven by increasing R&D spending and demand for drug safety testing.
Recent Initiatives: Recent initiatives include acquisitions to expand service offerings and investments in new technologies.
Summary
Charles River Laboratories is a strong player in the preclinical research market, benefiting from its diversified service offerings and global presence. The company's growth is dependent on R&D spending in the pharmaceutical and biotechnology sectors. Charles River should be wary of increased competition, regulatory changes, and economic downturns which affect R&D spending. Diversifying its services and expanding into emerging markets will help mitigate risk.
Similar Companies
IQV
IQVIA Holdings Inc
IQV
IQVIA Holdings Inc
LH
Laboratory Corporation of America Holdings
LH
Laboratory Corporation of America Holdings
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst estimates
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Charles River Laboratories
Exchange NYSE | Headquaters Wilmington, MA, United States | ||
IPO Launch date 2000-06-23 | Chairman, President & CEO Mr. James C. Foster J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 18700 | Website https://www.criver.com |
Full time employees 18700 | Website https://www.criver.com | ||
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.